董事会认为，战略合作将助力集团提升区域医疗资源整合与治理能力，进一步拓展西北地区市场，扩大 医学影像共享中心版图，符合公司及其股东的整体利益。 一脉阳光(02522)发布公告，公司近日与甘肃省庆阳市人民政府以及公司孵化的医学影像人工智能公司 上海影禾医脉智能科技有限公司(影禾医脉)订立战略框架合作协议。根据该战略框架合作协议，三方拟 就建设共享医学影像中心、影响云索引互联互通互认平台和医疗健康可信数据空间开展战略合作。战略 合作将通过建设区域共享型影像诊断中心与数字化平台，有效整合医疗资源，为当地医疗机构提供标准 化、高质量的医学影像服务。战略合作还将推进医疗信息化平台建设，构建互联互通互认体系与健康可 信数据空间，助力落实分级诊疗、加强各级医疗机构协同、解决数据孤岛与重复检查等问题，提升资源 利用效率，并推动医疗数据资产化进程。 ...

董事会认为，战略合作将助力集团提升区域医疗资源整合与治理能力，进一步拓展西北地区市场，扩大 医学影像共享中心版图，符合公司及其股东的整体利益。 战略合作将通过建设区域共享型影像诊断中心与数字化平台，有效整合医疗资源，为当地医疗机构提供 标准化、高质量的医学影像服务。战略合作还将推进医疗信息化平台建设，构建互联互通互认体系与健 康可信数据空间，助力落实分级诊疗、加强各级医疗机构协同、解决数据孤岛与重复检查等问题，提升 资源利用效率，并推动医疗数据资产化进程。 格隆汇11月24日丨一脉阳光(02522.HK)宣布，公司近日与甘肃省庆阳市人民政府(「庆阳市政府」)以及 公司孵化的医学影像人工智能公司上海影禾医脉智能科技有限公司(「影禾医脉」)订立战略框架合作协 议。根据该战略框架合作协议，三方拟就建设共享医学影像中心、影响云索引互联互通互认平台和医疗 健康可信数据空间开展战略合作。 ...

Core Viewpoint - The integration of obstetric services in Wangcang County is deemed necessary due to a significant decline in the number of births, leading to an oversupply of obstetric institutions and fragmented medical resources [1][2]. Summary by Sections Current Situation - The number of live births in Wangcang County has decreased from 1,604 in 2021 to 1,170 in 2024, with only 544 live births projected for the first half of 2025 [1]. - Obstetric services are currently provided by three institutions: the County Maternal and Child Health Hospital, the County People's Hospital, and the County Traditional Chinese Medicine Hospital, with no other medical institutions offering these services [1]. Need for Integration - The county's health bureau indicates that the decline in birth rates and the excessive number of obstetric institutions hinder the development of obstetric care, necessitating resource integration [2]. - Integration is expected to save medical resources, promote differentiated development among county-level medical institutions, and enhance the capacity for critical obstetric care [2]. Proposed Integration Plan - The health bureau has received agreement from the three medical institutions to consolidate obstetric services into the County Maternal and Child Health Hospital [2]. - Several factors must be considered for this integration, including the need for improved infrastructure and service capabilities at the County Maternal and Child Health Hospital, as well as coordination between the County People's Hospital and the maternal health facility for critical care [3]. - The health bureau is actively working on a comprehensive integration plan, which will be submitted for government approval [3].

Core Insights - The collaboration between Meinian Health and Shenzhen Luohu District People's Hospital aims to enhance medical services through complementary strengths, focusing on patient convenience and joint development [1][3]. Group 1: Collaboration Details - The partnership will facilitate seamless referrals and green channel services, allowing clients to access high-quality medical resources at Shenzhen Luohu District People's Hospital [2][3]. - The hospital will assign dedicated personnel to coordinate referrals and surgical services for Meinian Health clients, ensuring smooth processes [3]. Group 2: Specialized Medical Services - The collaboration will leverage the hospital's expertise in diagnosing and treating conditions such as lung nodules and varicose veins, providing specialized services to Meinian Health clients [2][4]. - The integration of services aims to create a one-stop solution for patients, streamlining the process from screening to diagnosis and treatment [2][4]. Group 3: Future Prospects - Meinian Health plans to continue exploring innovative medical service models in partnership with Shenzhen Luohu District People's Hospital, enhancing the overall healthcare experience for residents [4].

Core Viewpoint - The company, New Mile Health Technology Group Co., Ltd., has achieved significant growth in revenue and profit in 2024, driven by strategic restructuring, resource integration, and technological innovation in the healthcare sector [1][3]. Group 1: Financial Performance - In 2024, the company reported a revenue of 3.799 billion yuan and a net profit attributable to shareholders of 115 million yuan, marking a substantial year-on-year increase of 296.13% [1]. Group 2: Healthcare Services Development - The company is addressing the uneven distribution of medical resources in China by expanding its healthcare services through strategic restructuring and scale expansion, focusing on regional medical needs [3]. - Key hospitals under the company, such as Siyang Hospital and Lankao First Hospital, are enhancing their specialized capabilities and optimizing their discipline layout to improve patient care [3]. - The company has successfully created a virtuous cycle of "scale expansion - quality improvement - efficiency growth" by enhancing operational efficiency and cost control, leading to increased market share and patient satisfaction [3]. Group 3: Pharmaceutical Manufacturing - With over 20 years in pharmaceutical manufacturing, the company has established a competitive advantage in the traditional Chinese medicine sector, centered around its core product, "Duyiwei Capsule" [3]. - The "Duyiwei Capsule" has been recognized for its unique efficacy, high safety, and low treatment costs, being included in the Chinese Pharmacopoeia and various national medical insurance directories [3]. Group 4: Marketing and Brand Development - The company has developed a dual-driven marketing model of "distribution + specialized academic promotion," investing in academic promotion for nearly a decade to build a stable sales team [4]. - The "Duyiwei" trademark was awarded "China Famous Trademark" in 2024, further solidifying its market position [4]. Group 5: Industry Trends and Future Outlook - The healthcare industry in China is experiencing favorable conditions due to an aging population and increasing chronic disease prevalence, with over 260 million chronic disease patients [4]. - The company plans to continue focusing on its dual main businesses of "healthcare + pharmaceuticals," enhancing regional medical center construction and increasing investment in innovative drug research and development [4].